Session Title: AMD I
Session Date/Time: Thursday 26/09/2013 | 08:30-10:30
Paper Time: 09:10
Venue: Hall 1 (Level 2)
First Author: A.Hautamaki FINLAND
Co Author(s): J. Kivioja S. Vavuli M. Liinamaa P. Onkamo
The study was conducted to evaluate the association of single nucleotide polymorphisms (SNPs) of interleukin-8 (IL-8), vascular endothelial growth factor, erythropoietin, complement factor H, complement component C3, and LOC387715 genes with the response to bevacizumab-treatment in exudative age-related macular degeneration (AMD).
The medical records of patients with exudative AMD receiving their first loading dose of three intravitreal anti-VEFG-injections at the Department of Ophthalmology, Helsinki University Central Hospital, Finland, between January 2007 and December 2008 were analyzed retrospectively. The DNA samples were collected to further study the factors affecting treatment response.
Clinical records, smoking history, optical coherence tomographies (OCTs), and angiographies of 96 bevacizumab-treated exudative AMD patients were analyzed and blood DNA was collected. Based on the disappearance of intra- or subretinal fluid in OCT patients were graded as responders, partial responders or nonresponders after three initial treatment visits and a median time of 3.5 months. The associations between SNPs, lesion characteristics, and anatomical and functional treatment response were analyzed.
IL-8 promoter polymorphism -251A/T was significantly associated with persisting fluid in OCT. The A allele was more frequent in nonresponders than in responders (P = 0.033). In multivariate modeling the AA genotype of -251A/T (P = 0.043), and occult (P = 0.042) or predominantly classic (P = 0.040) lesions predicted poorer outcome. Visual acuity (VA) change was better in responders than in nonresponders (P = 0.006). Baseline lesion size (P = 0.006) and retinal cysts after the treatment (P < 0.001) correlated with less VA gain.
The genotype AA of interleukin-8 promoter polymorphism -251A/T was associated with persisting intra- or subretinal fluid in exudative age-related macular degeneration patients after the initial treatment with intravitreal bevacizumab. Interleukin-8 seems to modulate the response to anti-VEGF therapy at least during the first months of the treatment.